Background—In patients with acute coronary syndromes and planned percutaneous
coronary intervention, the Trial to Assess Improvement in Therapeutic Outcomes by …

BACKGROUND: Dual antiplatelet therapy with aspirin and clopidogrel is standard for
prevention of thrombotic complications of percutaneous coronary intervention (PCI) …

Background—On average, acute coronary syndrome patients treated with prasugrel
experience fewer ischemic complications, but more bleeding, than those receiving …

Background Dual-antiplatelet therapy with aspirin and a thienopyridine is a cornerstone of
treatment to prevent thrombotic complications of acute coronary syndromes and …

Objectives: We evaluated the relative contributions of the loading and maintenance doses of
prasugrel on events in a TRITON–TIMI 38 (TRial to Assess Improvement in Therapeutic …

Abstract Aims In the TRial to assess Improvement in Therapeutic Outcomes by optimizing
platelet inhibitioN with prasugrel Thrombolysis In Myocardial Infarction 38 (TRITON-TIMI 38) …

Background and objectives We sought to determine the frequency of use and association
between prasugrel and outcomes in acute coronary syndrome patients undergoing …

Objectives: This study sought to evaluate the efficacy of prasugrel versus clopidogrel in ST-
segment elevation myocardial infarction (STEMI) by the timing of percutaneous coronary …

Abstract Aims In the TRITON-TIMI 38 trial, greater platelet inhibition with prasugrel reduced
the first occurrence of the primary endpoint (cardiovascular death, MI, or stroke) compared …

Objectives: The goal of this study was to determine whether there is a relationship between
aspirin dose and the potent antiplatelet agent prasugrel in the TRITON–TIMI 38 (Trial to …